4D Molecular 制药

最新新闻

• 评级变动
  Jefferies Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/3/30
• 评级变动
  Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/4/13
• 评级变动
  Cantor Fitzgerald Upgrades 4D Molecular Therapeutics(FDMT.US) to Buy Rating, Announces Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)
  TipRanks · 2026/7/21
• 评级变动
  Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/5/9
• 评级变动
  Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $38
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• Morgan Stanley Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Chardan Capital Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
  TipRanks · 2026/8/14
• Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
  TipRanks · 2026/9/21
• 评级变动
  Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)
  TipRanks · 2026/7/21
• 评级变动
  BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/7/21
• Cantor Fitzgerald Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36
  \u5e02\u573a\u8d44\u8baf · 2026/8/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。